Want to see IN:KRSNAA full AI Analyst Report?
Top Page
Krsnaa Diagnostics Limited
(KRSNAA)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹532.00
▼(-4.87% Downside)
Action:Reiterated
Date:08/26/26
The score is driven mainly by solid revenue growth and an improved balance sheet, offset by weak free cash flow generation and uneven cash conversion. Technicals are broadly neutral, and valuation appears reasonable but not strongly compelling given the low dividend yield.
Positive Factors
Sustained Revenue Growth
Revenue increased from approximately 4.55B in 2022 to 7.73B in 2026, showing sustained demand expansion rather than a single-period uplift. Continued growth can broaden the operating base and support stronger utilization across pathology and imaging services over the next several quarters.
Negative Factors
Persistently Negative Free Cash Flow
Free cash flow remained negative in most reported years, including 2026, indicating that operating cash generation has not consistently covered investment needs or working-capital demands. Persistent cash outflows can limit internally funded expansion and increase reliance on financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Revenue increased from approximately 4.55B in 2022 to 7.73B in 2026, showing sustained demand expansion rather than a single-period uplift. Continued growth can broaden the operating base and support stronger utilization across pathology and imaging services over the next several quarters.
Read all positive factors
Krsnaa Diagnostics Limited (KRSNAA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹16.35B
Dividend Yield0.4%
Average Volume (3M)9.95K
Price to Earnings (P/E)16.8
Beta (1Y)0.99
Revenue Growth10.19%
EPS Growth20.99%
CountryIN
Employees3,296
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)30.04
Shares Outstanding32,438,670
10 Day Avg. Volume4,059
30 Day Avg. Volume9,950
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)1.72
Price to Sales (P/S)2.18
P/FCF Ratio-17.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)49.17
Revenue Forecast (FY)₹9.64B
Krsnaa Diagnostics Limited Business Overview & Revenue Model
Company Description
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers mammography, stress tests, dual-energy X-ray absorptiometry scans, bone mineral density tests, computed tomography scans, and magnetic resonance imaging services, as well ...
How the Company Makes Money
Krsnaa Diagnostics makes money primarily by providing diagnostic services and charging for tests and imaging procedures. Its revenue model is largely service-led and includes: (1) Pathology (clinical laboratory) revenue: fees earned from processin...
Krsnaa Diagnostics Limited Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
78
Positive
Cash Flow
42
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.15B | 7.73B | 7.17B | 6.20B | 4.87B | 4.55B |
| Gross Profit | 3.68B | 3.01B | 5.48B | 2.05B | 4.13B | 3.95B |
| EBITDA | 2.26B | 2.55B | 2.16B | 1.61B | 1.42B | 1.46B |
| Net Income | 974.60M | 1.01B | 776.08M | 568.37M | 621.11M | 683.88M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 18.24B | 12.82B | 11.72B | 9.10B | 8.76B |
| Cash, Cash Equivalents and Short-Term Investments | 3.61B | 3.61B | 684.36M | 535.45M | 1.09B | 2.42B |
| Total Debt | 0.00 | 5.34B | 2.04B | 1.60B | 324.81M | 409.92M |
| Total Liabilities | -9.80B | 8.43B | 3.99B | 3.62B | 1.71B | 2.07B |
| Stockholders Equity | 9.80B | 9.80B | 8.83B | 8.10B | 7.39B | 6.84B |
Cash Flow | ||||||
| Free Cash Flow | -516.97M | -942.60M | -393.00M | -1.70B | -650.59M | -37.95M |
| Operating Cash Flow | 518.74M | 1.25B | 873.27M | 243.45M | 763.01M | 1.28B |
| Investing Cash Flow | -1.04B | -4.04B | -996.09M | -1.29B | -1.09B | -2.41B |
| Financing Cash Flow | 592.91M | 3.06B | 137.53M | 841.87M | -331.45M | 1.76B |
Krsnaa Diagnostics Limited Technical Analysis
Negative
559.25
Price Trends
541.44
Negative
543.24
Negative
582.81
Negative
Market Momentum
-13.86
Positive
35.34
Neutral
26.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KRSNAA, the sentiment is Negative. The current price of 559.25 is above the 20-day moving average (MA) of 526.18, above the 50-day MA of 541.44, and below the 200-day MA of 582.81, indicating a bearish trend. The MACD of -13.86 indicates Positive momentum. The RSI at 35.34 is Neutral, neither overbought nor oversold. The STOCH value of 26.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KRSNAA.
Krsnaa Diagnostics Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹72.74B | 50.42 | ― | 2.04% | 21.99% | 12.77% | |
74 Outperform | ₹319.97B | 58.77 | ― | 0.84% | 14.29% | 5.55% | |
71 Outperform | ₹149.06B | 79.30 | ― | 0.14% | 20.18% | 24.71% | |
63 Neutral | ₹16.53B | 45.98 | ― | 0.31% | 23.31% | 7.56% | |
61 Neutral | ₹16.35B | 16.77 | ― | 0.40% | 10.19% | 20.99% | |
59 Neutral | ₹113.09B | 56.06 | ― | 0.37% | 21.80% | 31.84% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:KRSNAA
Krsnaa Diagnostics Limited
504.10
-268.69
-34.77%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,906.30
353.10
22.73%
IN:METROPOLIS
Metropolis Healthcare Ltd.
545.15
55.73
11.39%
IN:SURAKSHA
Suraksha Diagnostic Ltd.
317.40
0.09
0.03%
IN:THYROCARE
Thyrocare Technologies Ltd
457.00
-2.55
-0.55%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,447.25
462.37
46.95%
Krsnaa Diagnostics Limited Corporate Events
Krsnaa Diagnostics Taps AZmed’s Radiology AI to Scale X-ray Reporting
Oct 22, 2026
Krsnaa Diagnostics has announced a strategic collaboration with Paris-based radiology AI specialist AZmed to evaluate the latter’s AZtrauma solution, part of the Rayvolve suite, for detecting and triaging fractures, joint effusions and dislo...
Krsnaa Diagnostics Secures Exchange Nod for Promoter-Focused Warrant Issue
Oct 8, 2026
Krsnaa Diagnostics Limited has received in-principle approvals from BSE and the National Stock Exchange of India to issue 1,621,000 convertible warrants on a preferential basis to its promoter and promoter group. The warrants are convertible into ...
Krsnaa Diagnostics Wins Exchange Nod for Preferential Issue of Convertible Warrants
Oct 8, 2026
Krsnaa Diagnostics Limited has received in-principle approvals from BSE and the National Stock Exchange of India for the issue of 1,621,000 convertible warrants to its promoter and promoter group on a preferential basis, each warrant convertible i...
Krsnaa Diagnostics Wins Shareholder Nod for Promoter-Backed Warrant Issue
Sep 18, 2026
Krsnaa Diagnostics Limited has secured shareholder approval to issue up to 1,621,000 warrants, convertible into equity shares of Rs 5 each, on a preferential basis to its promoter and promoter group. The approval was obtained via a postal ballot c...
Krsnaa Diagnostics Announces Dispatch of Annual Report and AGM Notice
Sep 6, 2026
Krsnaa Diagnostics Limited has completed the dispatch of its Annual Report along with the notice convening its 16th Annual General Meeting to shareholders. The company has also published statutory advertisements about this completion and the AGM n...
Krsnaa Diagnostics Clears Q1 Results, Sets AGM and Approves Promoter Warrants Issue
Aug 13, 2026
Krsnaa Diagnostics Limited’s board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and cleared the director’s report and accompanying annexures for the 2025-26 financial year. T...
Krsnaa Diagnostics Posts 22% Revenue Growth as Rajasthan Network Goes Live and Promoters Back Expansion
Aug 13, 2026
Krsnaa Diagnostics reported a 22% year-on-year rise in Q1 FY2027 revenue from operations to ₹2,355 million, driven by growth in its established business and contributions from newly commissioned projects. Like-for-like projects grew about 12...
Krsnaa Diagnostics Releases Investor Presentation on Q1 FY2026-27 Results
Aug 13, 2026
Krsnaa Diagnostics Limited has released an investor and analyst presentation detailing its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The disclosure, made under SEBI’s Listing Obligations and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.